Drugs / Ratutrelvir
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07157007 | Sep 2025 → Feb 2026 overdue | COVID-19 | Traws Pharma, Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 9
| Date | Issuer | Release |
|---|---|---|
| 2026-02-19 | Traws Pharma, Inc. | Results Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza trawspharma.com ↗
Traws Pharma, Inc. (NASDAQ: TRAW, “Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today announced the completion of the clinical analysis of its 90-patient, open-label Phase 2 study of ratutrelvir, an investigational oral, ritonavir-free Mpro/3CL protease inhibitor, versus PAXLOVID ® in patients with mild-to-moderate COVID-19, together with a single arm in PAXLOVID ® -ineligible subjects. |
| 2026-01-26 | Traws Pharma, Inc. | Results Traws Pharma Completes Enrollment of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients; Announces Plans for Added Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza trawspharma.com ↗
Ongoing clinical results with ratutrelvir confirm a differentiated profile versus PAXLOVID ® with fewer adverse events, no viral rebounds to date and faster time to sustained symptom resolution |
| 2026-01-13 | Traws Pharma, Inc. | Results Traws Pharma Files Tivoxavir Marboxil Investigational New Drug (IND) Application for Influenza Therapy, and Provides Updated Results from the Ongoing Clinical Study of Ratutrelvir in PAXLOVID®-Eligible and Ineligible COVID-19 Patients trawspharma.com ↗
Updated clinical results with ratutrelvir confirm a differentiated profile versus PAXLOVID ® with fewer adverse events, no viral rebounds and faster time to sustained symptom resolution |
| 2025-12-17 | Traws Pharma, Inc. | Results Traws Pharma Reports Positive Interim Clinical Data with Ratutrelvir Versus PAXLOVID™, Shows Activity in PAXLOVID-Ineligible COVID-19 Patients trawspharma.com ↗ |
| 2025-08-18 | Traws Pharma, Inc. | Regulatory Traws Pharma Receives Approval to Proceed with Phase 2 COVID Studies with Ratutrelvir, Expects Results by Year-End 2025 trawspharma.com ↗
today announced receipt from the Human Research Ethics Committee (HREC) of approval to proceed with a Phase 2 study to evaluate ratutrelvir, a ritonavir-free treatment in newly diagnosed COVID subjects. |
| 2025-06-30 | Traws Pharma, Inc. | Regulatory Traws Pharma Advances Antiviral Pipeline with Multiple Regulatory Submissions trawspharma.com ↗
Phase 2 study protocol submitted to HREC to evaluate ratutrelvir in newly diagnosed COVID patients, with extensions to measure disease rebound and development of Long COVID |
| 2025-03-25 | Traws Pharma, Inc. | Results Traws Pharma’s COVID-19 Candidate, Ratutrelvir, Presented at ICAR trawspharma.com ↗
Data presented at ICAR 2025 shows that ratutrelvir is highly active against native virus and nirmatrelvir-resistant strains and omicron variants. |
| 2024-09-30 | Traws Pharma, Inc. | Results Traws Pharma Announces Positive Topline Phase 1 Results for COVID Candidate, Ratutrelvir, an Oral Mpro Inhibitor trawspharma.com ↗
Topline data indicate that administration of ratutrelvir, our product candidate for COVID, as monotherapy, for 10 days to healthy volunteers, showed no treatment related adverse events and demonstrated consistent plasma drug levels in the predicted therapeutic window. |
| 2024-05-23 | Traws Pharma, Inc. | Results Traws Pharma’s ICAR Poster Highlights Potency of COVID-19 Candidate trawspharma.com ↗ |
All press releases naming this drug 10 releases
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ratutrelvir | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07157007 ↗ |